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ABSTRACT
Driven by the growing recognition of the influence of the gut microbiota (GM) on
human health and disease, there is a rapidly increasing interest in understanding how
dietary components, pharmaceuticals and pre- and probiotics influence GM. In vitro
colon models represent an attractive tool for this purpose. With the dual objective of
facilitating the investigation of rare and expensive compounds, as well as an increased
throughput, we have developed a prototype in vitro parallel gut microbial fermentation
screening tool with a working volume of only 5 ml consisting of five parallel reactor
units that can be expanded with multiples of five to increase throughput. This allows
e.g., the investigation of interpersonal variations in gut microbial dynamics and the
acquisition of larger data sets with enhanced statistical inference. The functionality of
the in vitro colon model, Copenhagen MiniGut (CoMiniGut) was first demonstrated
in experiments with two common prebiotics using the oligosaccharide inulin and the
disaccharide lactulose at 1% (w/v). We then investigated fermentation of the scarce
and expensive human milk oligosaccharides (HMOs) 3-Fucosyllactose, 3-Sialyllactose,
6-Sialyllactose and the more common Fructooligosaccharide in fermentations with
infant gutmicrobial communities. Investigations ofmicrobial community composition
dynamics in the CoMiniGut reactors by MiSeq-based 16S rRNA gene amplicon high
throughput sequencing showed excellent experimental reproducibility and allowed us
to extract significant differences in gutmicrobial composition after 24 h of fermentation
for all investigated substrates and fecal donors. Furthermore, short chain fatty acids
(SCFAs) were quantified for all treatments and donors. Fermentations with inulin and
lactulose showed that inulin leads to a microbiota dominated by obligate anaerobes,
with high relative abundance of Bacteroidetes, while themore easily fermented lactulose
leads to higher relative abundance of Proteobacteria. The subsequent study on the
influence of HMOs on two infant GM communities, revealed the strongest bifidogenic
effect for 3′SL for both infants. Inter-individual differences of infant GM, especially
with regards to the occurrence of Bacteroidetes and differences in bifidobacterial species
composition, correlated with varying degrees of HMO utilization foremost of 6′SL and
3′FL, indicating species and strain related differences in HMO utilization which was
also reflected in SCFAs concentrations, with 3′SL and 6′SL resulting in significantly
higher butyrate production compared to 3′FL. In conclusion, the increased throughput
of CoMiniGut strengthens experimental conclusions through elimination of statistical
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interferences originating from low number of repetitions. Its small working volume
moreover allows the investigation of rare and expensive bioactives.
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INTRODUCTION
Growing evidence shows that human health and disease are linked to gut microbiota
(GM) composition and functionality (Marchesi et al., 2016). This has led to an increasing
interest in investigations on the effect of dietary components, pharmaceuticals, and pre-
and probiotics on GM composition and function (Payne et al., 2012). Human intervention
studies are the ‘‘gold standard’’ in the study of GM and GM-host interactions, but these are
also expensive and hampered by ethical constrains. Similarly, animal models are essential
for the study of e.g., the impact of GM on many diseases, but animal GM composition
differs from the human GM and for ethical reasons the use of animal experiments should
be minimised if alternatives are available (Fenwick, Griffin & Gauthier, 2009; Krych et al.,
2013).
In vitro colon models facilitate investigations circumventing ethical constrains and
lowering study costs. These models provide unlimited screening possibilities of new
products, facilitating continuousmonitoring and sampling possibilities under standardized
conditions. A variety of in vitro colon models exists as reviewed previously (Macfarlane &
Macfarlane, 2007; Payne et al., 2012; Venema & Van den Abbeele, 2013). The models range
from batch to continuous cultures, consisting of single or multistage setups. The latter
design facilitates the simulation of spatial, temporal, nutritional and physicochemical
properties of the colon through a series of three connected chemostats, simulating the
proximal, transverse and distal colon regions (Payne et al., 2012).
Along the colon a continuous increment in pH and lowered redox potential is seen
due to a varying degree of SCFAs production, cross-feeding of SCFAs by GM members,
absorption by the host and increased proteolysis (Fallingborg et al., 1993).
In vitro simulations of the colon which are operated with larger volumes do generally not
facilitate investigations on the GM modulating effects of expensive compounds or novel
synthesized materials only available in small amounts e.g., due to high costs. Furthermore,
the usually low throughput-number of larger in vitromodels with only a few or no technical
replicates is reducing the statistical strength of experimental data and scientific conclusions.
HMOs are a family of structurally diverse unconjugated glycans, which constitute the
thirdmost abundant humanmilk component (Newburg, 1996). HMOs display resistance to
the low pH in the infant’s stomach as well as hydrolysis by host enzymes and gastrointestinal
absorption (Engfer et al., 2000) and are selectively fermented by the infant GM. Variations
in infant GM composition due to feeding and deliverymode have been described, and inter-
individual differences in GM prevail even when grouped according to delivery and feeding
mode (Azad et al., 2013). Characteristic for breast-fed infants is the selective nourishment
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and support of a protective, co-evolved gut microbiota dominated by bifidobacteria and
Bacteroides (Bäckhed et al., 2005; Haarman & Knol, 2005).
HMOs are composed of lactose reducing ends elongated with up to 25 N -
acetyllactosamine units, which can be extensively fucosylated and/or sialylated through
R-glycosidic linkages (Ninonuevo et al., 2006). This translates to over 200 different known
human milk oligosaccharide (HMO) structures (Ninonuevo et al., 2006). Emerging data
indicates that HMO profiles are dynamic, revealing fluctuations between and within
lactation in individual mothers (Ninonuevo et al., 2006; Thurl et al., 2010; Totten et al.,
2012). Knowledge on the relationship between the levels of specific milk oligosaccharides
and their role in maternal and infant health and development is still scarce (Zivkovic et
al., 2011). However, in general HMOs are associated with an array of health benefits,
of which many are thought to be directly or indirectly associated with the infants gut
microbiota (Bode, 2012). Further, HMO shaped microbial communities can aid to prevent
the colonization by pathogens through competitive exclusion (Morrow et al., 2004). HMOs
have also been reported to act as decoy pathogen binding sites directly inhibiting the
adhesion and invasion of pathogenicmicrobes (Marcobal et al., 2010)modulating intestinal
epithelial cell growth and infant immune system as reviewed previously (Bode, 2006; Bode,
2012; German et al., 2008).
The utilization of specific HMOs by the infant GM is still being explored. HMO
consumption is conserved in some infant-associated types of bifidobacteria, such as the
B. longum subsp. infantis lineage, whereas other display strain-specific phenotypic variation
(LoCascio et al., 2007; Ward et al., 2006). Several studies have investigated the utilization
of HMOs in anaerobic cultures with single species (Marcobal et al., 2010; Sela et al., 2012;
Sela et al., 2011; Ward et al., 2007; Ward et al., 2006; Yu, Chen & Newburg, 2013), where
e.g.,Marcobal et al. (2010) reported the metabolization of HMOs by Bacteroides fragilis and
Bacteroides vulgatus strains with high efficiency.
Functional HMO alternatives such as galacto-oligosaccharides (GOS) are produced by
glycoside hydrolases (GH) using lactose as substrate (Torres et al., 2010) and fructo-
oligosaccharides (FOS), can be produced through transfructosylation of sucrose or
hydrolysis of inulin by endoinulinases (Singh & Singh, 2010), are the main prebiotics
currently added to infant formula (Rinne et al., 2005).
With the assumption that the human colon can be simulated in vitro in small volumes,
and with the dual objective of facilitating the investigation of rare and expensive
compounds, as well as an increase of throughput, we have developed a prototype in
vitro colon model with a working volume of only 5 ml mimicking an average colon
transit time of 24 h. Multiples of 5-plex CoMiniGuts can be aligned and constitute, in
combination with high throughput molecular biology techniques and advanced analytics,
an efficient screening platform to investigate GM dynamics and fecal metabolomics. Here
we demonstrate as proof of principle the use of CoMiniGut for the investigations of the two
common, well studied prebiotics inulin and lactulose. We then investigate the fermentation
of the rare and expensive compounds, and most original prebiotics, namely human milk
oligosaccharides and compare the effect with that of fructo-oligosaccharides (Bode, 2012;
Marcobal et al., 2010).
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MATERIAL AND METHODS
The CoMiniGut
The CoMiniGut prototype consists of a climate box with five parallel single-vessel,
stirred, anaerobic reactor units, which are pH monitored and controlled (Fig. 1). Each
anaerobic reactor unit consists of a fused quartz glass vial (FQ-2010, Fused quartz crucible,
cylindrical, 10 ml, OD 22 mm × H 33 mm, 5 ml working volume; AdValue Technology,
Tucson, AZ, USA) positioned in a 150 ml polymethylmethacrylat (PMMA) compartment.
Anaerobic conditions are achieved using either Anaerogen compact sachets (AN0020D;
ThermoScientific, Waltham, MA, USA) positioned inside the PMMA compartments or
via integrated gas in- and outlets for flushing the compartments with nitrogen (99.8%) to
maintain anaerobiosis (this also facilitates gas or headspace sampling). Resazurin soaked
indicators are used to signal anaerobiosis (Anaerobe Indicator Test; Sigma-Aldrich, St.
Louis, MO, USA). The lid of the PMMA compartments is composed of a PMMA ring and
an exchangeable vacuum greased silicon rubber septa (20420-U SUPELCO GR-2 Rubber
Sheet Stockmaterial; Sigma-Aldrich, St. Louis, MO, USA) containing a pH probe inlet.
The rubber septa are penetrable by needles for pH control, sampling, as well as feeding of
substrate if desired. The parallel alignment of the five reactor vessels in one unit is based
on a magnetic stirrer with five stirring positions. The climate box is kept at a temperature
of 37 ◦C by a circulating water bath connected to a heat-exchange plate inside the climate
box and an external temperature probe positioned in the box for feedback control. A
ventilation system secures even temperature distribution, and temperature logging (Temp
101A MadgeTech Temperature data logger) is performed throughout experiments. The
pH is monitored via a 6 channel pH meter and data logger (Consort multi-parameter
analyser C3040). The pH meter is connected to a laptop running in-house Matlab scripts
for pH control (ver. R2015a; The MathWorks, Inc., Natick, MA, USA), which regulates
a multichannel syringe pump charged with syringes containing 1 M NaOH. The syringes
(10 ml; BD Biosciences, San Jose, CA, USA) are connected via tubing (VWR) and injection
needles (Frisenette, Knebel, Østjylland, Denmark) into the fermentation compartments.
Fecal inoculum
For inulin and lactulose fermentations fecal samples from two healthy adults (F1, F2) were
individually homogenized in a 1:1 ratio with 1M PBS/20% glycerol (v/v) in a stomacher
bag for 2 × 60 s using the Stomacher (Stomacher 400; Seward, Worthing, UK) at normal
speed. For HMO fermentations fecal samples were prepared as stated above for two infant
fecal donors. Participants and parents of infants provided consent, sampling and use of
fecal material for inoculation of the CoMiniGut fermentations has been approved by the
Ethical Committee (E) for the Capital Region of Denmark (H-15001754).
Both infant donors were healthy males, approximately six months of age, born vaginally,
have been exclusively breast-fed and did not receive antibiotic treatment nor probiotics.
Fecal slurries, with a final glycerol concentration of 10% (a standard glycerol concentration
used for fecal transplants (Hamilton et al., 2012)) were then aliquoted into cryo vials and
stored at −60 ◦C until use.
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Figure 1 CoMiniGut model overview. 1. Climate Box, 2. Water bath, 3. Heating plate, 4. Temperature
probe, 5. Temperature data logger, 6. Ventilators, 7. Lab-jack table, 8. Magnetic stirrer, 9. PMMA com-
partment, 10. Reaction vial, 11. Gas inlet, 12. Gas outlet, 13. Flow meters, 14. Nitrogen/gas tap, 15. pH
probe and needle inlets, 16. Lid with septa, 17. Multichannel syringe pump, 18. pH meter, 19. Computer.
Full-size DOI: 10.7717/peerj.4268/fig-1
Fecal glycerol stocks were thawed and further diluted with 0.1 M PBS pH 5.6, ratio
1:4, on the day of the experiment. CoMiniGut reaction vessels containing 4.5 ml of media
were then inoculated with 0.5 ml of fecal slurry to achieve an inoculation at 10% of
the fermentation volume (hence 1% original fecal matter), diluting the glycerol out to
0.2% (v/v).The viability of feces derived microbiota of frozen and fresh fecal slurries was
evaluated through the counting of colony forming units (CFUs) on GAM and BHI agar
plates after anaerobic incubation for 72 h at 37 ◦C.
In vitro fermentation media and conditions
Stirred batch-culture fermentations (5 ml working volume) were set up and aseptically
filled with 4.5 ml basal medium (0.5 g/l bile salts, 2 g/l peptone water, 2 g/l yeast extract (all
purchased from Oxoid), 0.1 g/l NaCl, 0.04 g/l K2HPO4, 0.04 g/l KH2PO4 (all purchased
from Merck), 0.01 g/l MgSO4 × 7H2O, 0.01 g/l CaCl2 × 6H2O, 2 g/l NaHCO3− , Hemin
0.002 g/l, Vitamin K1 10 µl, Tween-80 2 ml (all purchased from Sigma-Aldrich), 0.5 g/l
L-Cysteine HCl (Calbiochem, San Diego, CA, USA)). Sigma colon medium was chosen for
screening purposes as also done previously (Fooks & Gibson, 2002; Sanz, Gibson & Rastall,
2005; Sarbini et al., 2013; Saulnier, Gibson & Kolida, 2008).
For the fermentations of inulin and lactulose the media was supplemented with 50 mM
MES 2-(N -morpholino) ethanesulfonic acid (Sigma-Aldrich, St. Louis, MO, USA) buffer,
divided into two batches and one batch was supplemented with 1% inulin (w/v) from
chicory (Sigma-Aldrich) and the other batch with 1% lactulose (w/v) (Sigma-Aldrich). For
the HMO fermentations basal colon media supplemented with 50 mM MES (Sigma-
Aldrich) buffer, was divided into five batches and four batches were supplemented
with each one of the four HMOs 1% (w/v). HMO used were 3-Fucosyllactose (3FL)
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(OligoTech, Crolles, France), 3-Sialyllactose (3SL) and 6-Sialyllactose (6SL) (Carbosynth,
Compton, UK), Oligofructose (FOS) (Orafti P95; Oreye, Belgium) and a carbohydrate
negative control. The fermentations were performed for each substrate and fecal sample
in quadruplicates. Fermentations were performed with pH control. The pH was set to
increase from 5.7 to 6.0 during the first 8 h of fermentation simulating pH conditions
prevalent in the proximal colon, followed by an 8 h pH increment from pH 6.0 to 6.5
representing the pH conditions in the transverse colon and finally a pH increment from 6.5
to 6.9 for distal colon. Samples were taken for endpoint analysis after 24 h of fermentation
as previously described (Glei et al., 2006; Kneifel, 2000; Stein et al., 2011). The HMOs were
fermented in quadruplicates, the negative control without HMOs are represented in
triplicates. GraphPad Prism software (Version 6.0) was used for statistical analyses of the
pH controlled fermentations.
DNA extraction
One ml of each fermentation endpoint (at 24 h) was pelleted via centrifugation at 13.000 g
for 10 min and gDNA was extracted from the pellet using the Power Soil Kit protocol
(MoBio Laboratories, Carlsbad, CA, USA). The FastPrep bead-beating step was performed
in 3 cycles of 15 s each at a speed of 6.5 M/s in a FastPrep-24TM Homogenizer (MP). DNA
quantity and quality were measured using a NanoDrop 1000 (Thermo Scientific, Waltham,
MA, USA).
16S rRNA gene library preparation
The fecal microbiota composition of in vitro fermentation samples were determined
using tag-encoded 16S rRNA gene MiSeq-based (Illumina, CA, USA) high throughput
sequencing. The V3 region of the 16S rRNA gene was amplified using primers
compatible with the Nextera Index Kit (Illumina, San Diego, CA, USA) NXt_338_F:
5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACWCCTACGGGWGGC
AGCAG-3′ and NXt_518_R: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGA
TTACCGCGGCTGCTGG-3′ (Ovreås et al., 1997) the PCR reactions and library
preparation was conducted as described in Kristensen et al. (2016).
High throughput sequencing and data treatment
The raw dataset containing pair-ended reads with corresponding quality scores were
merged and trimmed using fastq_mergepairs and fastq_filter scripts implemented in the
UPARSEpipeline. Theminimumoverlap lengthwas set to 10 base pairs (bp). Theminimum
length of merged reads was 150 bp, the maximum expected error E was 2.0, and the first
truncating position with quality score was N ≤ 4. Purging the dataset from chimeric reads
and constructing de novo Operational Taxonomic Units (OTU) were conducted using the
UPARSEpipeline (Edgar, 2013). TheGreenGenes (13.8) 16S rRNAgene collectionwas used
as a reference database (McDonald et al., 2012). Quantitative Insight IntoMicrobial Ecology
(QIIME) open source software (Caporaso et al., 2010) (1.7.0 and 1.8.0) was used for the
subsequent analysis steps. Principal coordinate analysis (PCoA) plots were generated with
the Jackknifed Beta Diversity workflow based on 10 UniFrac distance metrics calculated
using 10 subsampled OTU tables. The number of sequences taken for each jackknife subset
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was set to 90% of the sequence number within the most indigent sample, hence 77,000
reads per sample for the inulin and lactulose 16S rRNA gene amplicon sequencing based
analysis and 87,000 reads/sample for the HMO 16S rRNA gene amplicon sequencing based
analysis. Analysis of similarities (ANOSIM) was used to evaluate group differences using
weighted and unweighted (Lozupone & Knight, 2005) UniFrac distance metrics that were
generated based on rarefied (77,000 reads/sample and 87,000 reads/sample, respectively)
OTU tables. The relative distribution of the genera registered was calculated for unified and
summarized in genus level OTU tables. Alpha diversity measures expressed as observed
species values (sequence similarity 97%) were computed for rarefied OTU tables (77,000
reads/sample and 87,000 reads/sample respectively) using the alpha rarefaction workflow.
Differences in alpha diversity were determined using a t -test-based approach employing the
non-parametric (Monte Carlo) method (999 permutations) implemented in the compare
alpha diversity workflow. The ANOVA determined significance of quantitative (relative
abundance) association of OTUs with given categories, p values were False Discovery Rate
(FDR) corrected. These were calculated based on 1,000 subsampled OTU-tables rarefied
to an equal number of reads (77,000 reads/sample and 87,000 reads/sample, respectively).
SCFA extraction and analysis
SCFAs profiles were extracted from 1 ml of pH controlled fermentations. In brief: 2 ml
of 0.3 M oxalic acid was added to the sample and vortexed for 1 min, followed by
centrifugation at 2,800 g for 15 min. Subsequently 800 µl was filtered through 0.45 µm
pore size Ultrafree-MC-HV filters (Millipore, Cork, Ireland). 600 µl of the filtrate was
transferred into HPLC vials containing 30 µl of the internal standard 50 mM 2 ethyl
butyrate (Sigma-Aldrich), in water. The samples were then analyzed using GC-MS (Agilent
7890A GC and an Agilent 5973 series MSD; Agilent, Waldbronn, Germany). GC separation
was performed on a Phenomenex Zebron ZB-WAXplus column (30 m × 250 µm × 0.25
µm). A sample volume of 1 µl was injected into a split/split-less inlet at 285 ◦C using a
2:1 split ratio. Septum purge flow and split flow were set to 13 ml/min and 2 ml/min,
respectively. Hydrogen was used as carrier gas, at a constant flow rate of 1.0 ml/min.
The GC oven program was as follows: initial temperature 100 ◦C, equilibration time 1.0
min, heat up to 120 ◦C at the rate of 10 ◦C/min, hold for 5 min, then heat at the rate of
40 ◦C/min until 230 ◦C and hold for 2 min. Mass spectra were recorded in Selected Ion
Monitoring (SIM) mode and the following m/z ion were detected at a dwell time of 50
ms: 41, 43, 45, 57, 60, 73, 74, 84 and the MS detector was switched off during the 1 min
of solvent delay time. The transfer line, ion source and quadrupole MS temperatures were
set to 230, 230 and 150 ◦C, respectively. The mass spectrometer was tuned according to
manufacturer’s recommendation using perfluorotributylamine (PFTBA). Dilution series of
SCFAs standards of acetic, propionic, butyric, isobutyric, 2-methyl isobutyric, valeric and
isovaleric acid (Sigma-Aldrich) were prepared at the concentrations of 1.000, 0.500, 0.250,
0.125, 0.060 and 0.030 mM for the construction of standard curves for quantification. For
the analysis of SCFAs in the HMO fermentations, the amounts were subtracted by the
SCFAs produced in the control fermentations, in order to extract the HMO effect.
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SCFAs data analysis
Initial analysis and visualization of theGC-MSdatawas performedusingMSDChemStation
software (version E.02.02.1431; Agilent Technologies, Inc., Waldbronn, Germany). Mass
spectra of SCFAs were compared against the NIST11 library (NIST, Gaithersburg, MD,
USA). SCFAs peak areas were integrated from SIM chromatograms using in-house scripts
written in Matlab (ver. R2015a; The MathWorks, Inc., Natick, MA, USA). Two SCFAs,
2-methyl isobutyric acid and isovaleric acid, co-eluted at the retention time range of
4.22–4.45 min; peak areas were determined by de-convoluting these peaks using base
peaks at m/z ion 74 for 2-methyl isobutyric acid and m/z ion 60 for isovaleric acid. T -test
and one-way ANOVA with post-hoc tests (significance level 0.05) were performed using
GraphPad Prism.
RESULTS
Fermentations of inulin and lactulose
The pH-profiles of the inulin and lactulose fermentations with and without pH control
are displayed in Fig. 2. The pH controlled fermentations were conducted with an average
standard deviation of 0.07–0.10 pH units between experimental replicates over the course
of 24 h, with no significant difference between F1 and F2 fermentations for each treatment
(ANOVA, p= 0.4). Uncontrolled fermentations displayed an average standard deviation
ranging from 0.23 to 0.36 pH units and differed significantly (ANOVA p< 0.001). The
uncontrolled pH profiles displayed inter-individual differences as well as differences
between fermentation substrates.
16S rRNA gene amplicon sequencing analysis yielded 7.796.212 reads with an average of
194.905.3± 80.366.8 reads per sample fulfilling the quality control requirements (minimum
sequence length ≥ 180 bp, minimum average quality score ≥ 25). The alpha diversity of
the fecal donor GM used as fermentation inoculum in this study did not differ significantly
between the samples, with the number of observed species for F1 being 393 and for F2 318.
The mean phyla composition was dominated by Firmicutes (F1: 59.7%, F2: 46.7%) and
Bacteroidetes (F1: 37.2%, F2: 51.1%) for both donors with Cyanobacteria, Tenericutes,
Verrumicrobia, Proteobacteria, Actinobacteria, Lentisphaerae, and Fusobacteria all
constituting minor parts of the inoculum (0.01–1.5%). Principal Coordinates Analysis
(PCoA) revealed a clear separation between the GM of the fecal inoculum prior and after in
vitro fermentation (Fig. 3). Experimental replicates clustered together and statistical analysis
on unweighted and weighted UniFrac matrices revealed significant separation between the
treatments (ANOSIM unweighted inulin and lactulose F1 and F2 R-stat 0.1948, p-value
0.039; ANOSIM weighted inulin and lactulose F1and F2 R-stat 0.931, p-value 0.001) and
displayed a clear donor effect, (Fig. 3). The relative abundance of Bacteroidetes differed
significantly with 65% of the reads constituting Bacteroidetes for inulin versus 12% for
lactulose (p< 0.001). The abundance of Proteobacteria also differed significantly with a
mean relative abundance of 30% for inulin vs 79% for lactulose fermentations (p< 0.001)
(Fig. 4A). The bifidogenic effect of the two tested prebiotics differed between the two tested
GMs, with bifidobacterial abundance being significantly higher in inulin fermentations
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Figure 2 pH profiles of inulin and lactulose fermentations. Fermentation pH profiles of controlled and
uncontrolled inulin (A) and lactulose (B) (1% w/v) fermentations using fecal inocula from adult donors
F1 and F2 (n= 4, line is mean value, shadow area is convex hull).
Full-size DOI: 10.7717/peerj.4268/fig-2
for the GM of F2 (inulin 0.5% vs. lactulose 0.07%, p= 0.005), while for F1 the opposite
picture was seen with a stronger (though non-significant) bifidogenic effect for lactulose
(inulin 0.6% and lactulose 7.2%).
Seven SCFAs were successfully identified in the samples at a concentration range of
0.06–34 mM. In addition, one unknown peak at component retention time 5.85 min, was
consistently detected in all samples (Fig. S1). It was not possible to identify this compound
using the metabolite library in NIST11 (details found in Fig. S2). Individual GMs within
the lactulose treatment, differed significantly in production of propionic (p< 0.0001) and
acetic acid (p< 0.0001) (Fig. 4B). When fermenting inulin, the donor GM showed no
significant difference in propionic and butyric acid production. The individual average
SCFAs profiles (%) of the fermentations are shown in Fig. 4B.
SCFA production with inulin and lactulose as substrates differed for both donors with
regard to butyric acid levels, which were higher in inulin fermentations (1.28± 0.59 vs 0.06
± 0.05 mM, p= 0.003). Similarly, more isobutyric acid (0.12 ± 0.00 vs 0.09 ± 0.01 mM,
p= 0.05) and propionic acid (6.02 ± 1.90 vs 3.32 ± 1.24 mM, p= 0.006) was detected in
inulin fermentates compared to the lactulose fermentates.
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Figure 3 PCoA plot of 16S rRNA gene sequences. PCoA score plot of 16S rRNA gene tag-encoded se-
quence reads based on weighted UniFrac distance metrics (n= 4, for all six experimental conditions).
Full-size DOI: 10.7717/peerj.4268/fig-3
Fermentations of HMOs
Alpha diversity of the infant fecal samples did not differ significantly (t -stat p= 0.08). The
GM composition of both infant donors at the phyla level was dominated by Actinobacteria
p< 0.01 (B1 73.12%, B2 96.70%), but differed significantly in other phyla abundance
levels. The GM of baby 2 feces had relatively low abundance of Firmicutes (B1 14.40%,
B2 2.41%, p< 0.01) and Proteobacteria (B1 9.00%, B2 0.88%, p< 0.01) Bacteroidetes
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Figure 4 Phyla (A) and SCFA (B) composition of the inulin and lactulose fermentations. (A) Phyla
composition (as determined by 16S rRNA gene amplicon sequencing) of pH controlled fermentations
(24 h) of inulin and lactulose (1% w/v) using fecal inocula from adult donors F1 and F2 in CoMiniGut.
ANOVA analysis of F1 and F2 inulin fermentations revealed significant differences (phylum level) in the
relative abundances of Bacteroidetes, Proteobacteria and Firmicutes (p < 0.01), while no significant dif-
ferences were detected between donors for Fusobacteria (p= 0.1) and Actinobacteria (p= 0.5). Variation
between technical replicates was not significant (n= 4, F1 p= 0.4, F2 p= 0.4). For lactulose fermentations
all phyla differed significantly between the two donors (p≤ 0.05), while variation between technical repli-
cates was not significant for both donors, (n = 4, F1 p = 0.6; F2 p = 0.8). (B) Relative concentrations of
short chain fatty acid profiles of pH controlled CoMiniGut fermentations with inulin and or lactulose (1%
w/v) using fecal inocula from adults donors F1 and F2 (n= 4).
Full-size DOI: 10.7717/peerj.4268/fig-4
represented 0.009% of the relative abundance in baby 2 whereas they represented 3.25%
of the reads in baby 1.
Of the investigated HMOs 3′SL clearly had the strongest bifidogenic effect and induced
the highest relative abundance (21.5%) of Actinobacteria after 24 h of fermentation
followed by 3′FL (9.9%) and 6′SL (8.4%), 2.4% in FOS and 5.7% in the control, the
abundances differed significantly between treatments, p= 0.03 (Fig. 5).
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Figure 5 Average Phyla composition of HMO fermentations. Average Phyla composition, (relative %
fraction of total) all fermentations for baby 1 and baby 2 with 3’SL, 6’FL, 6’SL and FOS as substrates as de-
termined by 16S rRNA gene amplicon sequencing. 3’FL fermentations differed significantly in the relative
abundance of assigned phyla between donors p≤ 0.02, but no significant differences were found between
technical replicates (n= 4, B1 p= 0.7, B2 p= 0.6). For 3’SL fermentations significant differences between
donors were detected for Proteobacteria and Firmicutes p< 0.01, whereas no significant variation was de-
tected between technical replicates (n= 4, B1 p= 0.8, B2 p= 0.6). For 6’SL fermentations, relative abun-
dance were significantly different for all phyla p ≤ 0.05, whereas no significant variation was detected for
technical replicates (n= 4, B1 p= 0.8, B2 p= 0.5). For FOS significant differences were detected for Bac-
teroidetes, Firmicutes and Proteobacteria p ≤ 0.05, whereas no significant differences were detected be-
tween technical replicates (n = 4, B1 p = 0.8, B2 p = 0.5). For the negative control no significant differ-
ences between phyla composition were detected between donors ≥0.3 and technical replicates (n = 4, B1
p= 0.6, B2 p= 0.3).
Full-size DOI: 10.7717/peerj.4268/fig-5
Looking at the babies separately, the highest abundances ofActinobacteriawere identified
in fermentations supplemented with sialyated HMOs for baby 1 with 3′SL 17.3% and
16.2% for 6′SL supplemented fermentations (Fig. 5). In the fermentations of HMOs
inoculated with GM from baby 1 higher abundances of Actinobacteria were observed in
all supplemented media compared to the negative control with the exception of 3′FL. The
3′FL fermentation also displayed the highest abundance of Bacteroidetes (42.8%), while
Firmicutes were most abundant in the 3′SL fermentations (35.9%). Proteobacteria were
lower in HMO supplemented treatments compared with FOS and non-supplemented
control (Fig. 5). In fermentations inoculated with baby 2 GM, which barely contained
representatives of the phyla Bacteroidetes, the three sialyated supplemented fermentations
displayed the highest relative abundance of 25.7% Actinobacteria. Significant differences
in Actinobacteria were detected between treatments p= 0.015. In contrast to baby 1, 6′SL
did not induce growth of Actinobacteria in baby 2, to any larger extent.
For fermentations with GM of baby 1 (Table 1) significant differences in the relative
abundance of an unassigned Veillonellaceae (p= 0.0001) and the OTU Veillonella
(p= 0.0001), were identified between treatments. Both were low abundant OTUs (<1%)
in all fermentations, but growing in 3′FL fermentations with 2.8% and 5.5% relative
abundance respectively.
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Table 1 Species compositions of HMO fermentations with GM of baby 1.Microbiota composition of all fermentations (3’SL, 3’FL, 6’SL, FOS and
control) for baby 1, as determined by 16S rRNA gene amplicon sequencing.
BABY1 Control FOS 6SL 3SL 3FL p-value
;Actinobacteria Bifidobacteriaceae Bifidobacterium bifidum (*99.4) 0.03 0.05 0.21 0.21 0.05 0.28
; Bifidobacteriaceae Bifidobacterium longum 0.6 0.37 0.24 1.38 0.38 0.5
; Bifidobacteriaceae Bifidobacterium breve (*97.8) 2.53 3.68 15.76 15.68 1.99 0.35
;Bacteroidetes Porphyromonadaceae Parabacteroides distasonis 1.76 1.44 24.07 14.23 31.39 0.07
; Porphyromonadaceae Parabacteroides gordonii (*96.9) 0.01 0 0.12 0.06 0.17 0.06
; Other Other other 0.02 0.03 0.19 0.09 0.19 0.05
; Bacteroidaceae Bacteroides ovatus 1.31 0.32 0.84 0.78 1.08 0.65
; Bacteroidaceae Bacteroides caccae 0.46 3.61 0.39 0.37 0.58 0.19
; Bacteroidaceae Bacteroides 2.14 4.68 6.67 4.62 8.63 0.64
; Bacteroidaceae Bacteroides uniformis 0.19 0.19 0.59 0.39 0.25 0.64
; Bacteroidaceae Bacteroides acidifaciens 0.37 0.14 0.21 0.22 0.26 0.76
; Bacteroidaceae Bacteroides other 0.11 0.04 0.23 0.14 0.28 0.25
;Firmicutes Lactobacillaceae Lactobacillus zeae 0 0.2 0 0.11 0.01 0.75
; Clostridiaceae Clostridium other 11.15 9.6 9.81 13.51 5.54 0.85
; Clostridiaceae Clostridium perfringens 7.35 6.38 6.54 9.12 3.67 0.85
; Veillonellaceae 0.02 0.01 0.03 0.01 2.83 <0.001
; Veillonellaceae Veillonella 0.04 0.02 0.07 0.01 5.55 <0.001
; Clostridiaceae Clostridium 3.08 2.65 5.31 9.4 0.99 0.63
; Peptostreptococcaceae Clostridium other 0.05 0 0 0.43 0 0.67
; Other Other other 0.03 0.01 0.02 0.14 0.01 0.65
; Enterococcaceae Enterococcus 0.53 0.09 0.16 0.24 0.15 0.58
; Clostridiaceae 0.84 0.77 1.26 2.19 0.28 0.64
; Clostridiaceae Other other 0.33 0.27 0.31 0.62 0.15 0.34
; Enterococcaceae Other other 0.07 0.03 0.05 0.09 0.02 0.5
;Proteobacteria Enterobacteriaceae Dickeya 0.07 0.34 0.12 0.01 0.01 0.03
; Enterobacteriaceae Enterobacter other 0.32 0.58 0.16 0.03 0.07 0.15
; Enterobacteriaceae Klebsiella 19.74 23.69 6.18 0.6 1 0.18
; Enterobacteriaceae Other other 3.97 3.35 1.05 0.85 0.57 0.34
; Enterobacteriaceae Erwinia other 0.09 0.12 0.07 0.02 0.02 0.27
; Enterobacteriaceae 42.52 37.17 19 23.97 33.64 0.4
; Other Other other 0.12 0.04 0.06 0.11 0.1 0.54
In baby 1 phyla Bacteroidetes was represented by nine OTUs on the species level,
with the species Parabacteroides distasonis displaying the highest abundances in all HMO
fermentations (14–31%) compared to the control and FOS fermentations (1–2%) (Table 1,
included all OTUs with 0.03% relative abundance in at least one of the treatments).
Bifidobacterium breve was highly abundant in the 3′SL and 6′SL fermentations (15–16%) in
baby 1, but only constituting 2–4% of the GM in the 6′FL, FOS and control fermentations
(Table 1).
Baby 2 harbored four species of bifidobacteria, B. bifidum, B. adolescentis, B. longum
and B. faecale. B. bifidum was the most abundant bifidobacteria, reaching the highest
relative abundance in the 3′FL and 3′SL fermentations (at 5–13%) while constituting less
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Table 2 Species composition of HMO fermentations with GM of baby 2.Microbiota composition of all fermentations (3’SL, 3’FL, 6’SL, FOS and
control) for baby 2 as determined by 16S rRNA gene amplicon sequencing.
Baby 2 Control FOS 6SL 3SL 3FL p value
;Actinobacteria Bifidobacteriaceae Bifidobacterium bifidum 0.09 0.26 0.08 13.25 7.58 <0.001
; Bifidobacteriaceae Bifidobacterium adolescentis 0.04 0.17 0.03 10.37 5.64 <0.001
; Bifidobacteriaceae Bifidobacterium longum 0.07 0.19 0.06 1.94 2.14 0.02
; Bifidobacteriaceae Bifidobacterium fecale (*97.24) 0 0 0 0.15 0.12 0.04
;Firmicutes Ruminococcaceae 0.21 0 0 0 0 0.28
; Lachnospiraceae Blautia 0.91 0 0 0 0 0.26
; Staphylococcaceae Staphylococcus aureus 3.93 0 0 0 0 0.24
; Lachnospiraceae 0.44 0 0 0 0 0.23
; Clostridiaceae Clostridium 1.57 0 7.56 0 0 0.23
; Clostridiaceae 0.4 0 1.75 0 0 0.22
; Enterococcaceae Other other 0 0 0.09 0.04 0 0.21
; Clostridiaceae Clostridium other 0.18 0.02 0.77 0.02 0.01 0.2
; Clostridiaceae Other other 0.05 0 0.15 0 0 0.2
; Enterococcaceae Enterococcus 0.01 0.02 0.72 0.3 0.02 0.29
; Streptococcaceae Streptococcus 0 0 0.01 0 0 0.42
; Lactobacillaceae Lactobacillus 0 0.01 0.05 0.65 0.01 0.62
; Clostridiaceae Clostridium perfringens 0 0.01 0.01 0.01 0.01 0.91
;Proteobacteria Enterobacteriaceae Erwinia other 0.15 0.11 0.17 0.04 0.19 0.39
; Other Other other 0.23 0.24 0.32 0.28 0.43 0.44
; Enterobacteriaceae Klebsiella 11.2 7.21 19.89 1.41 11.38 0.44
; Enterobacteriaceae Proteus 0.01 0 0 0 0.01 0.21
; Enterobacteriaceae Enterobacter cloacae 0.01 0.02 0 0.07 0.13 0.07
; Enterobacteriaceae Enterobacter other 0.33 0.48 0.36 0.09 0.38 0.13
; Enterobacteriaceae 37.28 77.23 63.89 69.03 66.64 0.16
; Enterobacteriaceae Dickeya 0.05 0 0.02 0 0 0.29
; Enterobacteriaceae Other other 3.86 13.88 3.98 2.29 5.19 0.03
; Enterobacteriaceae Enterobacter ludwigii 0.02 0.05 0.01 0.01 0.01 0.04
; Enterobacteriaceae Trabulsiella 0.01 0.02 0.01 0.01 0.01 0.27
than 1% in the 6′SL, FOS and control fermentations (Table 2, included all OTUs with
at least 0.03% relative abundance in at least one of the treatments). The bifidobacterial
species of baby 2 did not seem to ferment 6′SL. This is in contrast to baby 1, where
especially Bifidobacterium breve increased in relative abundance, when growing with 6′SL
supplemented media. 3′FL induced the least bifidogenic effect in baby 1 with small increase
in growth of Bifidobacterium breve, but had the second largest bifidogenic effect for baby 2
promoting growth of Bifidobacterium bifidum (7.6%) and B. adolescentis (5.6%).
SCFAs results
When looking at the SCFAs excluding unknowns the HMO treatments did not differ
significantly from the control (p= 0.35), but display trends of increased amounts of
propionic acid in 3′FL and highest butyric acid in FOS. When subtracting the SCFAs
found in the control from all other treatments Fig. 6, it becomes clear that Isovaleric and
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Figure 6 SCFA content of HMO fermentates.Quantified SCFAs (µM) produced after 24 h of fermenta-
tion of 3’SL, 6’SL, 3’FL and FOS by GM of baby 1 and 2. Amounts displayed represent values after subtrac-
tion of SCFAs produced in the control fermentations.
Full-size DOI: 10.7717/peerj.4268/fig-6
Valeric acid as well as 2-Methyl-Butyric acid mainly originate from substrates derived from
media and or feces. For both babies marked substrate effects on SCFAs-production were
observed. For baby 1, with significantly higher propionic acid production (p< 0.006) and
lower amount of butyric acid (p= 0.01) in the 3′FL fermentations compared to 3′SL, 6′SL
and FOS (Fig. 6). For baby 2, with the same pattern of significantly higher propionic acid
production in the 3′FL treatment (p< 0.0001) and lower butyric acid production compared
to the other treatments. A significant difference was detected for FOS fermentations, with
higher butyric acid production in fermentations with baby 1 GM (p= 0.01), Fig. 6.
DISCUSSION
Here we describe a novel, low-volume in vitro colon model with increased throughput.
CoMiniGut’s automated pH control set-up allows a flexible experimental design, with
optional settings for e.g., the simulation of only one colon region within the vessel or—as
presented in this study—the passage through the colon simulated by a pH increment over
time. Sampling of fermentate is facilitated at all times through a needle inlet. Similarly,
standard media can be altered and different feeds can be added gradually or at specific time
points in a programmed manner via a syringe pump.
Due to the small amount of fecal sample needed for the inoculations of each experiment
in CoMiniGut (250 µg of the fecal matter for the inoculation of five reactors), fecal cryo-
stock libraries can be constructed, that way facilitating multiple experimental repetitions,
something that is not possible, when fresh inoculum is used. Frozen stocks furthermore
facilitate an increased comparability between the donors, as samples can be processed
consistently from delivery to inoculation. A synchronized delivery of fresh fecal material
especially from e.g., infants is difficult to achieve. No significant differences in culturable
cell counts were observed between fresh fecal samples and the frozen samples, using the
same conditions as for CoMiniGut fecal inoculum implemented in this study (Fig. S3)
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Due to its small working volume CoMiniGut will also allow for the investigation of
expensive compounds or novel synthesized materials only available in small amounts,
which otherwise would be very costly or simply impossible. For the conduction of a
fermentation at 1% (w/v) only 50 mg of substrate is needed per fermentation reaction.
The requirement of only small amounts of substrate and fecal material facilitates the
screening of a plethora of different bioactives, in different doses and combinations, for one
or multiple fecal donors.
Using inulin and lactulose as substrate for fermentations inoculatedwith fecal slurry from
two adult donors significant substrate as well as inter-individual differences in microbiota
composition and SCFAs-profiles were demonstrated. Rycroft et al. (2001) investigated in
vitro simulated colon fermentations of several prebiotics including inulin and lactulose
using fluorescence in situ hybridization (FISH) to investigate the effect on microbiota
composition. Similar to Rycroft et al. (2001) we observed higher acetic acid levels after 24
h of fermentation of lactulose in vitro compared to inulin fermentations, though in the
present study the differences in acetic acid production were not significant. Venema et al.
also investigated the effects of lactulose on the composition of GM and SCFAs in human
volunteers and using the TIM-2 in vitro model. They, similar to the present study, found
low levels of butyrate production when fermenting lactulose in vitro (Venema et al., 2003).
Further, when comparing the ratios of the SCFAs (butyrate, propionate and acetate) it
is seen that the ratios of SCFAs found in our study are comparable to those observed by
Venema et al. (2003) in the adaptedmicrobial communities. This shows that SCFAs-results
obtained using the CoMiniGut are comparable to existing in vitro models with a higher
working volumes and lower throughput. The model further facilitated the fermentations
of the rare and expensive HMOs only available in small amounts with two infant GMs.
We have extracted inter-individual difference of HMO utilization capacity especially with
regards to 6-sialyated HMOs.
The site of sialyation 3 vs 6′SL impacts the degree of gut microbial growth and its
utilization depends on the metabolic capacity and the ability to utilize it within a given
microbial consortium. In this study we have found the strongest average bifidogenic effect
to be induced by 3′SL overall when looking at both infants. The lack of a bifidogenic effect
in the 6′SL-supplemented fermentations of baby 2 compared to the significant population
(≈16%) of Actinobacteria in 6′SL fermentations of GM from baby 1 (Fig. 5) is striking.
The GM of both infants harbored different bifidobacteria species. While both babies
harboured members of Bifidobacterium bifidum and B. longum, the GM of baby 1
also harboured Bifidobacterium breve, whereas baby 2 harboured B. adolescentis and
Bifidobacterium faecale. None of the bifidobacterial species present in the baby 1 GM
did increase in relative abundance during 6′SL fermentations (Table 1), whereas
Bifidobacterium breve (baby 2) grew in 6′SL fermentations. Different Bifidobacterial species
have varying physiologies leading to varying capacities of HMO utilization, and even strain
dependent utilization of HMOs has for instance been described for Bifidobacterium breve
(LoCascio et al., 2007; LoCascio et al., 2009; Ruiz-Moyano et al., 2013). It has been suggested
that B. longum subsp. infantis has an inherent and constitutive ability to process sialyated
compounds (Yu, Chen & Newburg, 2013). Nevertheless the B. longum strain of baby 2 did
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not seem to utilize 6′SL, which might be due to the specific site of sialyation. Another
explanation for the observed discrepancies is a syntrophic interaction between members
of the phyla Bacteroidetes, especially Parabacteroides distasonis, which are present in baby
1 but barely present in baby 2, and bifidobacteria.
Also, the utilization of 3′FL varies between baby 1 and baby 2. It is possible that this
is due to different strains of the species B. bifidum and B. longum in baby 2 vs. baby 1.
Nevertheless, it is also possible that the discrepancies between baby 1 and baby 2 relate to
the difference in overall microbial community and the presence of Bacteroidetes, which are
capable of HMOutilization. Yu, Chen & Newburg (2013) reported that when supplemented
with 3′FL, all Bifidobacterium spp. and Bacteroides spp. displayed appreciable induction of
Alfa-L-Fucosidase, AFU activity and consumed 40% or greater of the 3′FL in their study.
In the present study it is hence likely that Bacteroidetes thrive on 3′FL and compete with
the bifidobacterial strains explaining comparably lower bifidobacterial abundance in baby
1, when growing together with 3′FL utilizing Bacteroidetes.
CONCLUSIONS
The construction of fecal libraries of specific target groups such as babies, healthy adults,
elderly, diabetics, or obese donors allows for the assessment of single or multiple dietary
components, and their impact on individual gut microbial populations and subsequent
changes to their metabolism. In combination with advanced high throughput sequencing
protocols CoMiniGut constitutes an excellent tool for the investigation of not only bacterial
species but also interactions between bacteriophages and eukaryotic microorganisms and
various microbe-microbe and microbe-bioactive interactions in vitro. In this study we
show superior advantages of the newly developed in vitro colon model with regards to its
throughput, reproducibility and its potential application for the investigation of rare and
expensive compounds. To conclude, the CoMiniGut facilitates next generation in vitro
colon simulations with high statistical inference and simultaneous reduction of resources.
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